Plasma Cell Dyscrasias
At Montefiore Einstein Hematology (Blood Disorders), you can access exceptional care for plasma cell dyscrasias. As a global leader in hematology, we are an academic-based, national and international referral site for the most complex and high-risk cases. For over a century, we have been at the forefront of innovation, research and clinical care for all types of blood disorders.
Our team of hematologists is passionate about uncovering the latest diagnostic approaches and treatments that can improve outcomes.
At Montefiore Einstein Hematology (Blood Disorders), you can expect compassionate, personalized, research-driven treatment plans that meet the highest standards for quality and safety. By combining innovative therapies with proactive patient outreach, we strive to elevate the standard of care and significantly enhance outcomes for those living with plasma cell dyscrasias.
If you need care of a plasma cell dyscrasia (specific diseases listed and described below), turn to our dedicated providers who will develop a highly personalized treatment plan.
Montefiore Einstein offers the following content from the health information library of the National Institutes of Health’s National Library of Medicine and the National Heart, Lung and Blood Institute.
What Are Plasma Cell Dyscrasias?
Plasma cell dyscrasias are a group of disorders caused by the abnormal growth of plasma cells in the bone marrow, leading to the overproduction of monoclonal proteins (M proteins) in the blood. These conditions range from benign forms, such as monoclonal gammopathy of undetermined significance (MGUS), which require periodic physical examination and laboratory monitoring, to more aggressive cancers like multiple myeloma, where early diagnosis and treatment is critical in controlling the disease and preventing complications.
Types of Plasma Cell Dyscrasias
Plasma cell dyscrasias encompass a range of conditions, each with distinct characteristics.
- Multiple myeloma: the most serious form; overproduction of plasma cells results in bone damage and bone pain, kidney dysfunction, anemia and an increased risk of fractures
- Plasmacytoma: a solitary lesion of abnormal plasma cells usually in the bone which can cause bone pain or sometimes pathologic fracture
- Smoldering multiple myeloma: Plasma cells cause an elevated M protein but no symptoms. This has a higher risk of progression to myeloma and needs close monitoring.
- Monoclonal gammopathy of undetermined significance (MGUS): a precursor condition where abnormal plasma cells produce monoclonal proteins without causing symptoms, though it may progress to more serious disorders over time
- Light chain amyloidosis: Plasma cells produce an M protein that misfolds and deposits in organs and tissues causing organ damage such as kidney or heart failure.
- Waldenström macroglobulinemia (also called lymphoplasmacytic lymphoma): a rare type of non-Hodgkin lymphoma which results in excessive production of an immunoglobulin M (IgM) monoclonal protein that can cause hyperviscosity (or thick blood) and potential organ damage.
- POEMS syndrome: a complex disorder that presents with symptoms including polyneuropathy, organ enlargement, endocrinopathies, monoclonal protein production and skin changes
Causes of Plasma Cell Dyscrasias
The exact cause of plasma cell dyscrasias is not fully understood, but genetic mutations and environmental factors are believed to contribute. Risk factors include advanced age, exposure to radiation or toxic chemicals, infections, obesity and a family history of plasma cell disorders. Some conditions, such as MGUS, may remain stable, while others, like multiple myeloma, can progress over time.
Signs & Symptoms of Plasma Cell Dyscrasias
Symptoms vary significantly depending on the specific type of plasma cell dyscrasia. There are no symptoms in MGUS or smoldering myeloma. Many of the other pathologic conditions can be associated with persistent fatigue, frequent infections, unexplained weight loss and kidney dysfunction. Patients with multiple myeloma may experience bone pain, while patients with Waldenström macroglobulinemia may experience neurological symptoms due to blood thickening, while those with POEMS syndrome may develop skin changes, hormonal imbalances and nerve damage.
Diagnosing Plasma Cell Dyscrasias
Diagnosis involves a combination of laboratory tests, imaging studies and bone marrow biopsy. Blood tests such as serum protein electrophoresis (SPEP) and free light chain assays help detect abnormal protein levels. Advanced imaging, including magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, is used to assess bone damage and organ involvement. Bone marrow biopsy confirms the presence and extent of abnormal plasma cell proliferation.
Treating Plasma Cell Dyscrasias
Treatment depends on both the severity and the type of condition. MGUS often requires monitoring, while multiple myeloma and amyloidosis may require chemotherapy, immunotherapy or targeted treatments. High-dose chemotherapy followed by autologous stem cell transplantation is an option for eligible patients. Supportive therapies include medications to strengthen bones, manage hyperviscosity and treatments to reduce the risk of infections. Montefiore Einstein Hematology (Blood Disorders) offers cutting-edge treatments, clinical trials and personalized care to improve patient outcomes.